Table 2 SIRT2 deletion versus clinicopathological outcomes in the prostate cancer TCGA database (n = 499)
|  | SIRT2 Deleted (n = 30) | SIRT2 Diploid (n = 452) | P |
|---|---|---|---|
Age (Median/IQR) | 64(61.75–66.75) | 61(56–66) |  |
TNM stage | |||
 T1 | 0 | 2(0.4%) |  |
 T2 | 5(16.67%) | 164(40.2%) |  |
 T3 | 22(73.34%) | 276(61.2%) |  |
 T4 | 3(10%) | 9(2%) | 0.01 a |
 N1 | 8(27%) | 79(17.4%) | 0.22 |
 M+ |  | 3 |  |
Recurrence | |||
 Yes | 10(33.34%) | 81(17.9%) |  |
 No | 15(50%) | 290(64%) | 0.04 a |
Bilateral | 29(96%) | 435(96%) | 1 |
LNDa dissection | 29(96%) | 421(90%) | 0.7 |
Nodes (Median/IQR) | 7(4–16) | 9(5–16) |  |
Positive margins | 16(53%) | 152(33.6%) | 0.04 a |
Complete remission | 9 (30%) | 164(33.6%) | 0.8 |
Partial remission | 4 (13%) | 29(6.4%) | 0.14 |
Biochemical relapse | 3 (20%) | 48(10.6%) | 0.13 |